Rezera (proposed Nasdaq: RZRA) prepares IPO for cardiovascular inflammation programme
The company formerly known as NodThera intends to fund pivotal development of ruvonoflast in peripheral artery disease.
Get analysis like this in your inbox.
Join investors and analysts following Lex Commentary.
Rezera has outlined plans for a US initial public offering, seeking capital to advance its NLRP3 inhibitor ruvonoflast. Its filing identifies RZRA as the proposed Nasdaq symbol; the company is not yet trading under that ticker.
The principal intended use of proceeds is a planned Phase 3 study in peripheral artery disease, together with commercial-readiness work and earlier pipeline development. Offering size and pricing have not yet been set out.
The move follows a strategic focus on cardiovascular inflammation under the Rezera name. The company had previously explored ruvonoflast in obesity-related inflammation, including alongside semaglutide, but selected peripheral artery disease as its lead pivotal indication.
For prospective investors, the financing is tied to a clear clinical transition. The opportunity depends on demonstrating meaningful benefit in the intended patient population, not merely reducing inflammatory biomarkers. IPO proceeds could fund that test; the filing itself does not establish either the final capital raised or the probability of clinical success.